✨ Free AI Report
Arcturus Therapeutics Holdings Inc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Arcturus Therapeutics Holdings Inc
Company Research

Arcturus Therapeutics Holdings Inc: Business Overview, Financials & Competitive Analysis

Arcturus Therapeutics is a clinical-stage mRNA medicines company focused on rare diseases including cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, plus infectious disease vaccines. The company utiliz...

Analyst-debate audio for Arcturus Therapeutics Holdings Inc

AskCyborg analysts argue the bull and bear cases for Arcturus Therapeutics Holdings Inc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Platform-driven mRNA biotech with differentiated delivery technology and promising rare disease programs, but faces...

Read the full analyst-debate transcript →
Industry Biotechnology - mRNA Therapeutics & Rare Genetic Diseases
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Arcturus Therapeutics Holdings Inc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Arcturus Therapeutics Holdings Inc Overview

Pro stress-test →

Arcturus Therapeutics is a clinical-stage mRNA medicines company focused on rare diseases including cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, plus infectious disease vaccines. The company utilizes its proprietary LUNAR® lipid nanoparticle technology platform to deliver mRNA therapeutics and has demonstrated promising Phase 2 interim data in both CF and OTC programs.

Strategic Profile

Pro stress-test →

Arcturus differentiates through its LUNAR delivery platform designed for tissue-specific mRNA targeting, enabling treatment of genetic disorders where conventional therapies are limited. The company is advancing multiple pipeline candidates toward pivotal studies, with regulatory alignment meetings planned for early 2026 and commercial partnerships including CSL for vaccine commercialization.

Competitive Landscape

Pro stress-test →

Arcturus competes in the rare disease mRNA therapeutics space against companies like Moderna, Intellia Therapeutics, Sarepta Therapeutics, Sangamo Therapeutics, and BioCryst Pharmaceuticals. The company's competitive advantage centers on its LUNAR lipid nanoparticle technology designed for liver and respiratory tissue targeting, though it faces competition from larger, better-capitalized biotech firms.

Industry Context

Arcturus Therapeutics Holdings Inc operates in Biotechnology - mRNA Therapeutics & Rare Genetic Diseases.

Key facts

Founded: 2013 · Headquarters: San Diego, California · Revenue: $110M · Market cap: $323M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Arcturus Therapeutics Holdings Inc.

  • ARCT-032 CF Phase 2 interim data (Oct 2025) showed mucus volume reductions in 4 of 6 Class I patients with robust safety; expanded 12-week study planned for H1 2026
  • ARCT-810 OTC deficiency Phase 2 demonstrated statistically significant improvements in glutamine levels with positive safety profile; regulatory alignment for pivotal trials expected H1 2026
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Arcturus scheduled to report 4Q and FY 2025 results with corporate update on March 3, 2026
  • January 2026CEO Joseph Payne presented at J.P. Morgan Healthcare Conference
  • +2 moreTrack every material event for Arcturus Therapeutics Holdings Inc as it happens. Explore monitoring →
Get alerted when Arcturus Therapeutics Holdings Inc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ModernaLarge-cap mRNA therapeutics and vaccine platform company→Intellia TherapeuticsGene editing and mRNA-based rare disease therapies→Sarepta TherapeuticsGene therapy and RNA medicine for rare diseases→Sangamo TherapeuticsGene editing platform for genetic disorders→

Compare Arcturus Therapeutics Holdings Inc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Arcturus Therapeutics Holdings Inc operates in Biotechnology - mRNA Therapeutics & Rare Genetic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - mRNA Therapeutics & Rare Genetic Diseases research →
NEW · MCP server

Ask your AI assistant about Arcturus Therapeutics Holdings Inc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Arcturus Therapeutics Holdings Inc and its top competitor on Cyborg Score”
“What did Arcturus Therapeutics Holdings Inc do this quarter?”
“Is Arcturus Therapeutics Holdings Inc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Arcturus Therapeutics Holdings Inc do?+
Arcturus Therapeutics is a clinical-stage mRNA medicines company focused on rare diseases including cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, plus infectious disease vaccines. The company utiliz...
What is Arcturus Therapeutics Holdings Inc's Cyborg Score?+
Arcturus Therapeutics Holdings Inc has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Arcturus Therapeutics Holdings Inc's main competitors?+
Named competitors include Moderna, Intellia Therapeutics, Sarepta Therapeutics, Sangamo Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Arcturus Therapeutics Holdings Inc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Arcturus Therapeutics Holdings Inc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Arcturus Therapeutics Holdings Inc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - mRNA Therapeutics & Rare Genetic Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Arcturus Therapeutics Holdings Inc4Moderna, Inc.